PRMT5 and medulloblastoma: A variety of PRMT5 enzymatic inhibitors are currently applied in clinical trials of myelodysplastic syndrome, acute myeloid leukaemia, breast cancer and B cell non-Hodgkin lymphoma, prompting for further investigation in medulloblastoma [NCT03614728, NCT03573310, NCT02783300] (160).